Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Randomized Clinical Phase 3 Trial of Toripalimab Plus Concurrent Chemo-radiotherapy vs Concurrent Chemo-radiotherapy Alone for Unresectable Locally Recurrent Nasopharyngeal Carcinoma

NCT04453813 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT04453813
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04453813 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Randomized Clinical Phase 3 Trial of Toripalimab Plus Concurrent Chemo-radiotherapy vs Concurrent Chemo-radiotherapy Alone for Unresectable Locally Recurrent Nasopharyngeal Carcinoma
Lead sponsor
Sun Yat-sen University
Phase
Phase 3
Overall status
Recruiting
Start date
July 3, 2020
Completion date
July 31, 2027
Enrollment
226 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy, nasopharyngeal carcinoma, pd-1 treatment, radiotherapy